Combating Illicit Xylazine Act
The source supplies the latest action, but no lifecycle stage.
Latest action (16 Sep 2026): Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 623.
What this bill does
H.R. 1266, the Combating Illicit Xylazine Act, would place xylazine—an animal sedative increasingly found mixed into illicit drug supplies—into Schedule III of the Controlled Substances Act. It defines the drug legally, sets rules for who may lawfully possess it as an "ultimate user," and directs that manufacturers, prescribers, and pharmacies follow Schedule III requirements, with certain transition periods: security-standard capital expenses for existing manufacturers are waived, labeling and packaging rules are delayed one year, and practitioner registration rules are delayed 60 days. The bill also adds xylazine to the DEA's ARCOS drug-tracking system.
The bill primarily affects veterinarians, pharmacies, drug manufacturers, and law enforcement, as well as people who legally use xylazine for animal care, government animal-control programs, or wildlife management. It directs the U.S. Sentencing Commission to review and, if appropriate, update federal sentencing guidelines for offenses involving xylazine, and requires the Justice Department and FDA to report to Congress on xylazine's illicit use, trafficking patterns, and related substances within 18 months, with a follow-up report after four years.
The bill was introduced in February 2025, referred to the Energy and Commerce and Judiciary Committees, and reported with amendments in September 2026. It passed the House by voice vote on September 15, 2026, and now goes to the Senate for consideration.
Plain-English summary generated by Bill100 AI from the official record. Always verify against the source below.
Official summary
Combating Illicit Xylazine Act
This bill regulates xylazine under the Controlled Substances Act (CSA).
Xylazine, also known as tranq, is a nonopioid sedative and pain reliever that is approved for use in animals. Recently, the Drug Enforcement Administration (DEA) has reported an increase in trafficking of fentanyl mixed with xylazine.
This bill adds xylazine, including its salts, isomers, and salts of isomers, to schedule III of the CSA. Schedule III controlled substances, including anabolic steroids, buprenorphine, and ketamine, have less potential for abuse than a schedule I or II substance, have a currently accepted medical use, and have low or moderate risk of dependence if abused.
Under the bill, manufacturing, distributing, or dispensing xylazine, or possessing with intent to manufacture, distribute, or dispense xylazine for illicit use is subject to criminal penalties under the CSA. The bill also requires xylazine transactions to be tracked in the drug reporting system maintained by the DEA.
The bill exempts from registration under the CSA persons and entities that possess xylazine (1) lawfully dispensed by a veterinarian or pharmacy and (2) for an animal or for use in certain animal-control or wildlife programs.
The bill also exempts xylazine manufacturers from the CSA's physical security requirements.
Finally, the bill requires the DEA, in coordination with the Food and Drug Administration, to report on (1) the prevalence and impact of illicit xylazine use in the United States, and (2) updated information on the prevalence and proliferation of xylazine trafficking and misuse in the United States.
Timeline
16 Sep 2026
Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 623.
Common questions
- What does H.R. 1266 do?
- H.R. 1266, the Combating Illicit Xylazine Act, would place xylazine—an animal sedative increasingly found mixed into illicit drug supplies—into Schedule III of the Controlled Substances Act. It defines the drug legally, sets rules for who may lawfully possess it as an "ultimate user," and directs that manufacturers, prescribers, and pharmacies follow Schedule III requirements, with certain transition periods: security-standard capital expenses for existing manufacturers are waived, labeling and packaging rules are delayed one year, and practitioner registration rules are delayed 60 days. The bill also adds xylazine to the DEA's ARCOS drug-tracking system. The bill primarily affects veterinarians, pharmacies, drug manufacturers, and law enforcement, as well as people who legally use xylazine for animal care, government animal-control programs, or wildlife management. It directs the U.S. Sentencing Commission to review and, if appropriate, update federal sentencing guidelines for offenses involving xylazine, and requires the Justice Department and FDA to report to Congress on xylazine's illicit use, trafficking patterns, and related substances within 18 months, with a follow-up report after four years. The bill was introduced in February 2025, referred to the Energy and Commerce and Judiciary Committees, and reported with amendments in September 2026. It passed the House by voice vote on September 15, 2026, and now goes to the Senate for consideration.
- Has H.R. 1266 become law?
- The source does not supply a confirmed lifecycle stage for H.R. 1266. Check the latest action and official source below.
- Who sponsored H.R. 1266?
- H.R. 1266 was sponsored by Rep. Panetta, Jimmy [D-CA-19] (D-CA), with 114 cosponsors.
- What's the latest action on H.R. 1266?
- Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 623. (16 Sep 2026).
Related bills in Crime and Law Enforcement
Enhancing Detection of Human Trafficking Act
National Coordination Center and Commercial Cyber Capabilities Codification Act
Supporting the goals and ideals of "National Nonviolence Week" to raise awareness of youth violence in the United States.
Anthony Amoros Law Right to Know Act
More bills from Rep. Panetta, Jimmy [D-CA-19]
Mali Security Partnership and Counterterrorism Act
Farmers Lifeline to Overcoming Disasters (FLOOD) Act
Lindsey O. Graham Sanctioning Russia and Iran Act of 2026
BRIDGE Africa Act
Bill100 mirrors the public U.S. legislative record from Congress.gov and GovTrack and adds plain-English AI summaries. It is an information tool, not legal, compliance or lobbying advice, and it is not affiliated with the U.S. Congress or any government agency. AI summaries can simplify or omit detail — every bill links to the official source; verify there before you rely on it.